ClinicalTrials.gg
SuspendedNCT06355908ENHANCINGUpdated Oct 1, 2026

IL13Rα2 CAR-T for Patients With r/r Glioma

A Phase 1 interventional study of IL13Rα2 CAR-T in Glioma, sponsored by Yang Zhang. Suspended at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Yang Zhang · Phase 1, Interventional, and Treatment

How we know

Why this study was suspended
Temporarily suspended for HGRAC filing requirements
Updated Oct 1, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Glioma with a site in China — 70 open to participants now, 82 under way, 3 of them phase 3. Glioma · China.

Planned enrollment
69th of 112
30 · median 40
Started
2024
with 16 others
Phase 1
36 of 162
18 open now
Registered
114th of 162
by date

Among the 162 studies in Glioma with a site in China, this one is the 69th largest by planned enrollment of the 112 interventional ones that give a count, is one of 17 that started in 2024, is one of 36 in phase 1, and was the 114th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

70 of the 162 studies in Glioma with a site in China are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Glioma with a site in China, or all of them as a file.
02

Study summary

This is a dose exploration clinical trial to assess the safety and feasibility of the IL13Ra2-targeted CAR-T in glioma.

Read the detailed description

Interleukin 13 receptor subunit alpha-2 (IL13Ra2A) is a high-affinity membrane receptor of the anti-inflammatory Th2 cytokine IL13, which is overexpressed in glioma and correlated with poor prognosis.

Chimeric antigen receptor (CAR) T cell therapy is a promising treatment approach for many malignancies. IL13Ra2-targeted CAR-T cells are under investigation in several clinical trials in primary CNS malignancies.

The investigators now designed a new structure CAR targeted IL13Ra2, and initiated a single arm, open, dose exploration clinical trial to evaluate the safety, tolerability, clinical efficacy, and pharmacokinetic characteristics of IL13Rα2 CAR-T for patients with glioma. This clinical trial will enroll 12-30 cases of patients with IL13α2-positive recurrent or refractory WHO grade 4 glioma (r/r WHO4 glioma), aiming to find the maximum tolerable dose (MTD), the recommended phase 2 dose (RP2D) and preliminary efficacy of the new structure IL13Ra2 CAR-T.

03

Conditions studied

  • Glioma

Browse trials for

Keywords

  • r/r WHO4 glioma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18-75 years (including 18 and 75 years old).
  2. scale score (KPS)≥50.
  3. Subjects with WHO grade 4 gliomas who have or progressed during or after standard treatments such as surgery, radiotherapy, and chemotherapy.
  4. Tumor with IL13Rα2 positive expression.
  5. Availability in collecting peripheral blood mononuclear cells (PBMCs).
  6. Adequate laboratory values and adequate organ function.
  7. Patients with childbearing/fathering potential must agree to use highly effective .

Exclusion criteria

Exclusion criteria:

  1. Pregnant or breastfeeding females.
  2. to bevacizumab.
  3. Within 5 days prior to the infusion of CAR-T cells, subjects receiving systemic administration of with dosage more than 10mg/d prednisone or the equivalent doses of other steroids (not including inhaled corticosteroid).
  4. Comorbid with other uncontrolled .
  5. Active immunodeficiency virus () or virus or virus or tuberculosis infection.
  6. diseases.
  7. Severe or uncontrolled psychiatric diseases or condition that could increase adverse events or interfere the evaluation of outcomes.
  8. Subjects who have previously received cell therapy (such as TCR-T, CAR-T, TIL, etc.).
  9. Subjects with other conditions that would interfere trial participation at the investigator's discretion.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    IL13Rα2 CAR-T

    Biological: IL13Rα2 CAR-T

    Biological: IL13Rα2 CAR-T

Interventions

  • BiologicalIL13Rα2 CAR-T

    The IL13Rα2 CAR-T cells will be administered via intraventricular infusion every 2 weekly via an Ommaya reservoir.

06

What researchers measure

Primary outcomes

  1. Safety of IL13Rα2 CAR-T

    The safety of IL13Rα2 CAR-T will be assessed based on the totality of dose-limiting toxicity (DLT) and adverse event (AE) data collected during this phase.

    Time frame: Day 0 - Day 730

Secondary outcomes

  1. Overall Response Rate (ORR)

    To evaluate the percentage of subjects who have a confirmed partial response (PR) and complete response (CR) per immunotherapy response assessment in neuro-oncology (iRANO) criteria.

    Time frame: Day 0 - Day 730

  2. Duration of Response (DOR)

    To evaluate the duration from the time that criteria are met for CR or PR per iRANO until disease progression or death due to any cause.

    Time frame: Day 0 - Day 730

  3. Progression Free Survival (PFS)

    To evaluate the time from the date of the first CAR-T infusion until disease progression per iRANO or death due to any cause.

    Time frame: Day 0 - Day 730

  4. Overall Survival (OS)

    To evaluate the time from the date of the first CAR-T infusion to death due to any cause.

    Time frame: Day 0 - Day 730

  5. Overall Survival (OS) at 6 months (OS6)

    To evaluate the percentage of survival subjects at 6 months after the first CAR-T infusion.

    Time frame: Day 0 - Day 180

  6. Overall Survival (OS) at 12 months (OS12)

    To evaluate the percentage of survival subjects at 12 months after the first CAR-T infusion.

    Time frame: Day 0 - Day 365

  7. The levels of IL13Rα2 CAR-T cell and IL13Rα2 CAR in the CSF and peripheral blood

    To detect the levels of IL13Rα2 CAR-T cell and IL13Rα2 CAR in the CSF and peripheral blood.

    Time frame: Day 0 - Day 730

  8. The levels of cytokines in the CSF and peripheral blood

    To detect levels of cytokines in the CSF and peripheral blood, cytokines will include IL-2, IL-6, IFN-γ, TNF-α, etc.

    Time frame: Day 0 - Day 730

Other outcomes

  1. The Exploratory Indicators

    To analyze tumor microenvironment and CAR-T cell infiltrative levels in tumor tissues before and after treatment by immunohistochemistry and/or transcriptome sequencing, and explore the tumor or immune cell markers related to disease prognosis and IL13Rα2 expression.

    Time frame: Day 0 - Day 730

07

Study locations

1 site
  • Beijing Tiantan Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2024 (actual). Primary completion is estimated for May 2027, 37 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: May 2026 → May 2027, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2024
First posted
Apr 10, 2024
StartActual
Mar 21, 2024
Primary completionEst.
May 1, 2027was May 2026
CompletionEst.
May 1, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 1, 2026→May 1, 2027
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion May 1, 2026→May 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06355908
Lead sponsor
Yang Zhang
Collaborators
TCRCure Biopharma Ltd.
Responsible party
Yang Zhang (Clinical Professor, Beijing Tiantan Hospital) — Sponsor-investigator
First posted
Apr 10, 2024
Start date
Mar 21, 2024
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Nan Ji, MD, PhD
principal investigator · Beijing Tiantan Hospital
Yang Zhang
principal investigator · Beijing Tiantan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion